Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ryan Weisman who wrote (405)	10/30/1997 8:28:00 PM
From: Cisco	Read Replies (1) \| Respond to of 1894

Ryan, Kinda odd that none of the news services have picked it up yet. I wonder if its going to get reported. Their last press release about the $8.5M credit line never got reported. Cisco

To: Ryan Weisman who wrote (405)	10/30/1997 10:57:00 PM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

It is only my "gut" intuition, coupled with a feel from watching AccuMeds' past management decisions on timing that leads me to believe a strong flurry of announcements are forthcoming. The "cards read" and I believe the street will hopefully be looking at the forward looking statements mentioning a strong back-order in the molecular-biology division. The cytopathology division has some strong competition as you well know. I do believe that for the company to "bank" on the cyto-division for the bulk of future positive earnings is tantamount to suicide. I for one am glad that the molecular-bio division is showing improved strength. Look at the 510(k) marketing clearance from the FDA to release an expanded Sensititre HP MIC panel for susceptibility testing of resistant Streptococcus pneumoniae and Haemophilus influenzae pathogens. Sell a couple of hundred thousand panels across the globe (southeast Asia too) and were talking major $$. Dispose and replenish, dispose and replenish... $$$$ Sure Cyto-pathology has the AcCell. Labs, like all sectors of the health care sector are looking to cut costs. The number of labs is diminishing due to consolidation. This means that AccuMed and the competition are all vying for a finite number of continually diminishing perspective buyers. There is also a new kid on the block; Chromavision (CVSN). Yes I know that they are not getting into the PAP Smear field. They don't even acknowledge AccuMed as being in there either according to their prospectus. There technology using computer assisted detection image analysis in conjuction with reactant stains sounds way too familiar to our own AccuMed's Sensititre and ESP Culture Systems. Do you think management ever thought of crossing reactants/broths with electrons....nah. I am getting way off the track here. Anyway, yes-AccuMed could have been a little more elaborative as to the increase in revenues... kind of like marketing/selling the sizzle and not the steak. We can only hope that the conference will prove a vehicle for letting individuals and companies know that there is an entity called AccuMed International, Inc. That they are a publicly traded concern, and there stock is way cheap when you figure it is one quarter (two months) away from expected break-even e.p.s. And that is trading in the range of a penny stock. Hope for the best Ryan, trick or treat?